Why the study?
The study aimed to assess the diagnostic utility of point-of-care high-sensitivity troponin within an emergency department chest pain pathway.
Does point-of-care high-sensitivity troponin I effectively risk stratify for acute myocardial infarction compared to laboratory high-sensitivity troponin T in emergency department patients?
Does point-of-care high-sensitivity troponin I effectively risk stratify for acute myocardial infarction compared to laboratory high-sensitivity troponin T in emergency department patients?
Point-of-care high-sensitivity troponin I safely ruled out acute myocardial infarction in a higher proportion of emergency department patients compared to standard laboratory testing, maintaining 100% sensitivity.
This prospective observational study aimed to assess the diagnostic utility of point-of-care (POC) high-sensitivity troponin (hs-cTn) within an ED chest pain pathway. Patients had paired laboratory hs-cTnT and POC hs-cTnI on arrival. Clinical care utilised the hs-cTnT result. Allocation to risk classes was compared between hs-cTnT and POC hs-cTnI. AMI was adjudicated blinded to the POC result. Of 184 patients, 14 (7.6%) had AMI. Twenty-one (11.4%) had AMI ruled out by hs-cTnT and 59 (32.1%) by POC, both with 100% sensitivity. The POC test returned invalid results in 17 patients (8.5%). A POC hs-cTnI assay within a clinical pathway may effectively risk stratify for AMI.
No takes yet. Share an insight, caveat, or question.
Fann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: